{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:08:34Z","timestamp":1792098514422,"version":"4.4.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jhep.2017.11.012","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T23:17:01Z","timestamp":1510701421000},"page":"238-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":455,"title":["Determinants of fibrosis progression and regression in NASH"],"prefix":"10.1016","volume":"68","author":[{"given":"Detlef","family":"Schuppan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rambabu","family":"Surabattula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2017.11.012_b0005","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.11.012_b0010","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_b0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jgh.12212","article-title":"Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches","volume":"28","author":"Schuppan","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_b0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.beem.2016.06.006","article-title":"Non-alcoholic fatty liver disease and risk of type 2 diabetes","volume":"30","author":"Lallukka","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.jhep.2017.11.012_b0025","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.012_b0035","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.27678","article-title":"Challenges and opportunities in drug and biomarker development for non-alcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop","volume":"61","author":"Sanyal","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0040","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hep.27720","article-title":"Strategies and endpoints of antifibrotic drug trials","volume":"62","author":"Torok","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0045","first-page":"1","article-title":"Design and estimation for the National Health Interview Survey, 2006\u20132015. National Center for Health Statistics. Vital and Health","volume":"2","author":"Parsons","year":"2014","journal-title":"Statistics"},{"key":"10.1016\/j.jhep.2017.11.012_b0050","unstructured":"Smits MM, Ioannou GN, Boyko EJ, Utzschneider KM. Non-alcoholic fatty liver CDC\u2019s Division of Diabetes Translation. United States Surveillance System available at http:\/\/www.cdc.gov\/diabetes\/data."},{"key":"10.1016\/j.jhep.2017.11.012_b0055","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.diabres.2013.03.010","article-title":"Diabetes in the Middle East and North Africa","volume":"101","author":"Zabetian","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jhep.2017.11.012_b0060","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/jgh.12106","article-title":"Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups","volume":"28","author":"Smits","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_b0065","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jpeds.2012.08.043","article-title":"Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988\u20131994 to 2007\u20132010","volume":"162","author":"Welsh","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.jhep.2017.11.012_b0070","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/hep.29068","article-title":"Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic","volume":"65","author":"Doycheva","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0075","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/ajg.2017.5","article-title":"Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of national health and nutrition examination survey data","volume":"112","author":"Kabbany","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.11.012_b0080","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"NASH CRN. Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/00365521.2016.1230779","article-title":"SAF score and mortality in NAFLD after up to 41 years of follow-up","volume":"52","author":"Hagstr\u00f6m","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.11.012_b0090","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_b0095","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2013.04.027","article-title":"Ratziu V; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver","volume":"59","author":"Pais","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_b0100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2016.02.023","article-title":"LIDO Study Group. Fatty liver is an independent predictor of early carotid atherosclerosis","volume":"65","author":"Pais","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_h0105","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_h0110","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.012_b0110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0115","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","author":"Estes","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0120","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.11.012_b0125","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D'Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0130","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.012_b0135","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/hep.28484","article-title":"Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention","volume":"63","author":"Vilar-Gomez","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.012_b0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10809","article-title":"Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity","volume":"482","author":"Henao-Mejia","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2017.11.012_b0150","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1136\/gutjnl-2012-303816","article-title":"Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice","volume":"62","author":"Le Roy","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.11.012_b0155","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0160","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2017.11.012_b0165","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1055\/s-0036-1593880","article-title":"The metabolic role of the microbiome: Implications for NAFLD and the metabolic Syndrome","volume":"36","author":"Quigley","year":"2016","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2017.11.012_b0170","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2012.06.031","article-title":"Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome","volume":"143","author":"Vrieze","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.012_b0175","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.gastro.2014.10.042","article-title":"Gut-liver axis in alcoholic liver disease","volume":"148","author":"Szabo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.012_b0180","article-title":"Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study","author":"Cobbold","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2017.11.012_b0185","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tem.2013.05.009","article-title":"Non-alcoholic steatohepatitis: a microbiota-driven disease","volume":"24","author":"Moschen","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jhep.2017.11.012_b0190","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0195","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.012_b0200","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/hep.21346","article-title":"Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease","volume":"44","author":"Merriman","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0205","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1053\/j.gastro.2009.12.003","article-title":"Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection","volume":"138","author":"McHutchison","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.012_b0210","unstructured":"Buzzetti E, et al. Collagen proportionate area (CPA) is an independent predictor of long-term outcome in patients with NAFLD. EASL 2017, Amsterdam. #PS-091."},{"key":"10.1016\/j.jhep.2017.11.012_b0215","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/hep.29090","article-title":"Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis","volume":"65","author":"Wang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0220","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/hep.28860","article-title":"Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood","volume":"65","author":"Decaris","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0225","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/s-0035-1562948","article-title":"Noninvasive evaluation of nonalcoholic fatty liver disease","volume":"35","author":"Castera","year":"2015","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2017.11.012_b0230","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or MRE to detect fibrosis in patients with non-alcoholic fatty liver disease: A meta-analysis","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0235","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/hep.26326","article-title":"Elastin-based molecular MRI of liver fibrosis","volume":"58","author":"Ehling","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0240","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/hep.28930","article-title":"Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model","volume":"65","author":"Zhu","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0245","doi-asserted-by":"crossref","unstructured":"Kim YO, Park KS, Engelbogen N, Diken M, Popov Y, Ross T, Schuppan D. Bimodal targeted near infrared\/positron emission tomography contrast agent to image liver fibrogenesis. AASLD 2017, abstract.","DOI":"10.1016\/S0168-8278(18)31057-2"},{"key":"10.1016\/j.jhep.2017.11.012_b0250","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_b0255","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMra1610570","article-title":"Use of liver imaging and biopsy in clinical practice","volume":"377","author":"Tapper","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.11.012_b0260","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.11.012_b0265","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1172\/JCI66028","article-title":"Evolving therapies for liver fibrosis","volume":"123","author":"Schuppan","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2017.11.012_b0270","doi-asserted-by":"crossref","first-page":"G807","DOI":"10.1152\/ajpgi.00447.2014","article-title":"Novel insights into the function and dynamics of extracellular matrix in liver fibrosis","volume":"308","author":"Karsdal","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2017.11.012_b0275","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/liv.12700","article-title":"Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C","volume":"35","author":"Nielsen","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.11.012_b0280","doi-asserted-by":"crossref","first-page":"G1009","DOI":"10.1152\/ajpgi.00283.2016","article-title":"Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy","volume":"311","author":"Karsdal","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2017.11.012_b0285","unstructured":"Charles ED, et al. A Phase 2 Study of BMS-986036 (Pegylated FGF21) in Obese Adults with Type 2 Diabetes and a High Prevalence of Fatty Liver. AASLD 2016 #33."},{"key":"10.1016\/j.jhep.2017.11.012_b0290","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/hep.23123","article-title":"Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies","volume":"50","author":"Popov","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3004700","article-title":"Therapy for fibrotic diseases: nearing the starting line","volume":"5","author":"Friedman","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2017.11.012_b0300","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMra1300575","article-title":"Fibrosis\u2013a common pathway to organ injury and failure","volume":"372","author":"Rockey","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.11.012_b0305","first-page":"184","article-title":"Antifibrotic therapies: Moving towards clinical translation","volume":"35","author":"Mehal","year":"2015","journal-title":"Sem Liver Dis"},{"key":"10.1016\/j.jhep.2017.11.012_b0310","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: Concept to treatment","volume":"62","author":"Friedman","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_b0315","doi-asserted-by":"crossref","first-page":"s83","DOI":"10.7861\/clinmedicine.15-6-s83","article-title":"Future mechanistic strategies for tackling fibrosis\u2013an unmet need in liver disease","volume":"15","author":"Fallowfield","year":"2015","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jhep.2017.11.012_b0320","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2016.05.051","article-title":"Comparison of gene expression patterns between mouse modelsof nonalcoholic fatty liver disease and liver tissuesfrom patients","volume":"151","author":"Teufel","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.012_b0325","article-title":"Gliptins suppress inflammatory macrophage activation to mitigate inflammation, fibrosis oxidative stress, and vascular dysfunction in models of nonalcoholic steatohepatitis and liver Fibrosis","author":"Wang","year":"2017","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.jhep.2017.11.012_b0330","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1126\/science.aam7928","article-title":"Inflammation and metabolism in tissue repair and regeneration","volume":"356","author":"Eming","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jhep.2017.11.012_b0335","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","author":"Friedman","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0340","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jhep.2017.11.012_b0345","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1194\/jlr.R066357","article-title":"Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis","volume":"57","author":"Hirsova","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhep.2017.11.012_b0350","doi-asserted-by":"crossref","unstructured":"Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol 2018;68:280\u2013295.","DOI":"10.1016\/j.jhep.2017.11.014"},{"key":"10.1016\/j.jhep.2017.11.012_b0355","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.95354","article-title":"Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis","volume":"2","author":"Greuter","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhep.2017.11.012_b0360","doi-asserted-by":"crossref","unstructured":"Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: Current and emerging. J Hepatol 2018;68:362\u2013376.","DOI":"10.1016\/j.jhep.2017.10.015"},{"key":"10.1016\/j.jhep.2017.11.012_b0365","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1053\/j.gastro.2014.01.061","article-title":"Vascular endothelial growth factor promotes fibrosis resolution and repair in mice","volume":"146","author":"Yang","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.012_b0370","article-title":"The good and the bad collagens of fibrosis \u2013 Their role in signaling and organ function","volume":"10","author":"Karsdal","year":"2017","journal-title":"Adv Drug Delivery Rev"},{"key":"10.1016\/j.jhep.2017.11.012_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2008-1040452","article-title":"Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins","volume":"10","author":"Schuppan","year":"1990","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2017.11.012_b0380","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-2001-17556","article-title":"Matrix as a modulator of hepatic fibrogenesis","volume":"21","author":"Schuppan","year":"2001","journal-title":"Sem Liver Dis"},{"key":"10.1016\/j.jhep.2017.11.012_b0385","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt1396","article-title":"Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone","volume":"26","author":"Sato","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2017.11.012_b0390","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/hep.27936","article-title":"Specific hepatic delivery of procollagen \u03b11(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis","volume":"62","author":"Jim\u00e9nez Calvente","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0395","article-title":"Inducible knockdown of procollagen I protects mice from liver fibrosis and leads to dysregulated matrix genes and attenuated inflammation","author":"Molokanova","year":"2017","journal-title":"Matrix Biol"},{"key":"10.1016\/j.jhep.2017.11.012_b0400","doi-asserted-by":"crossref","first-page":"G110","DOI":"10.1152\/ajpgi.00412.2010","article-title":"Hepatic stellate cells require a stiff environment for myofibroblastic differentiation","volume":"301","author":"Olsen","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2017.11.012_b0405","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/hep.21849","article-title":"Role of alphavbeta6 integrin in acute biliary fibrosis","volume":"46","author":"Wang","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0410","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1053\/j.gastro.2008.04.009","article-title":"Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression","volume":"135","author":"Patsenker","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.012_b0415","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jhep.2007.11.021","article-title":"Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies","volume":"48","author":"Popov","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_b0420","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hep.28274","article-title":"Integrin \u03b1v\u03b26 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis","volume":"63","author":"Peng","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0425","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","article-title":"Targeting of \u03b1v integrin identifies a core molecular pathway that regulates fibrosis in several organs","volume":"19","author":"Henderson","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2017.11.012_b0430","doi-asserted-by":"crossref","first-page":"288ra79","DOI":"10.1126\/scitranslmed.aaa5094","article-title":"The \u03b1v\u03b21 integrin plays a critical in vivo role in tissue fibrosis","volume":"7","author":"Reed","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2017.11.012_b0435","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.2208","article-title":"Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment","volume":"16","author":"Barry-Hamilton","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2017.11.012_b0440","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/hep.27320","article-title":"Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma","volume":"60","author":"Wong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0445","article-title":"GS-US-384-1497 Investigators. The ASK1 inhibitor Selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial","author":"Loomba","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0450","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/gutjnl-2016-312473","article-title":"Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal","volume":"66","author":"Ikenaga","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.11.012_b0455","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-2600(16)30421-0","article-title":"Efficacy of simtuzumab vs. placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial","volume":"5","author":"Raghu","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhep.2017.11.012_b0460","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1096\/fj.14-268425","article-title":"Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice","volume":"30","author":"Liu","year":"2016","journal-title":"FASEB J"},{"key":"10.1016\/j.jhep.2017.11.012_b0465","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jhep.2017.11.012_b0470","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2016.01.037","article-title":"Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease","volume":"150","author":"Anstee","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.012_b0475","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/15592294.2017.1294305","article-title":"Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin action","volume":"12","author":"de Mello","year":"2017","journal-title":"Epigenetics"},{"key":"10.1016\/j.jhep.2017.11.012_b0480","doi-asserted-by":"crossref","unstructured":"Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol 2018;68:268\u2013279.","DOI":"10.1016\/j.jhep.2017.09.003"},{"key":"10.1016\/j.jhep.2017.11.012_b0485","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2013.476","article-title":"The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis","volume":"109","author":"Singal","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.11.012_b0490","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2016.03.011","article-title":"PNPLA3 gene in liver diseases","volume":"65","author":"Tr\u00e9po","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_b0495","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrgastro.2015.35","article-title":"Alcoholic liver disease: mechanisms of injury and targeted treatment","volume":"12","author":"Louvet","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_b0500","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cld.2016.02.012","article-title":"Alcoholic Liver Disease: High risk or low risk for developing hepatocellular carcinoma?","volume":"20","author":"Joshi","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2017.11.012_b0505","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcmgh.2017.04.007","article-title":"Epigenetics and liver fibrosis","volume":"4","author":"Moran-Salvador","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_b0510","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1073\/pnas.1201840109","article-title":"Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis","volume":"109","author":"Kisseleva","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2017.11.012_b0515","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2012.06.036","article-title":"Deactivation of hepatic stellate cells during liver fibrosis resolution in mice","volume":"143","author":"Troeger","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.012_b0520","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.gastro.2007.05.012","article-title":"Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction","volume":"133","author":"Richardson","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.11.012_b0525","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.26937","article-title":"The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease","volume":"59","author":"Gadd","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0530","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/hep.1840130122","article-title":"Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis","volume":"13","author":"Davies","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0535","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-0676.1993.tb00603.x","article-title":"Bile duct changes in alcoholic liver disease. The Veterans Administration Cooperative Study Group","volume":"13","author":"Ray","year":"1993","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2017.11.012_b0540","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0002-9440(10)65299-6","article-title":"Oval cell numbers in human chronic liver diseases are directly related to disease severity","volume":"154","author":"Lowes","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2017.11.012_b0545","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/hep.20650","article-title":"Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis","volume":"41","author":"Clouston","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0550","first-page":"1221","article-title":"Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease","volume":"139","author":"Milani","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2017.11.012_b0555","first-page":"785","article-title":"Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis","volume":"148","author":"Pinzani","year":"1996","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2017.11.012_b0560","first-page":"3331","article-title":"Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans","volume":"118","author":"Omenetti","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2017.11.012_b0565","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ajpath.2013.03.018","article-title":"Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation","volume":"183","author":"Kuramitsu","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2017.11.012_b0570","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: immune regulation of wound healing in a solid organ","volume":"14","author":"Pellicoro","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2017.11.012_b0575","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2013.12.025","article-title":"Macrophage heterogeneity in liver injury and fibrosis","volume":"60","author":"Tacke","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_b0580","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.11.012_b0585","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1172\/JCI200522675","article-title":"Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair","volume":"15","author":"Duffield","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2017.11.012_b0590","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.22950","article-title":"Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis","volume":"50","author":"Karlmark","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.11.012_b0595","doi-asserted-by":"crossref","first-page":"G323","DOI":"10.1152\/ajpgi.00394.2009","article-title":"Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis","volume":"298","author":"Popov","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2017.11.012_b0600","doi-asserted-by":"crossref","first-page":"E3186","DOI":"10.1073\/pnas.1119964109","article-title":"Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis","volume":"109","author":"Ramachandran","year":"2012","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817324352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817324352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T04:36:26Z","timestamp":1570336586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827817324352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0168827817324352"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2017.11.012","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determinants of fibrosis progression and regression in NASH","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2017.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}